相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。BMT for Myelodysplastic Syndrome: When and Where and How
Akriti G. Jain et al.
FRONTIERS IN ONCOLOGY (2022)
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes
Brandon J. Aubrey et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades et al.
BLOOD ADVANCES (2022)
Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML PreClinical Models
Yannan Jia et al.
BLOOD (2021)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Naval Daver et al.
BLOOD (2021)
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres et al.
LEUKEMIA (2021)
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M. Hunter et al.
BLOOD ADVANCES (2021)
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival
Jacqueline S. Garcia et al.
LEUKEMIA RESEARCH (2021)
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Elsa Bernard et al.
NATURE MEDICINE (2021)
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S. Chien et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
Guillermo Montalban-Bravo et al.
Oncotarget (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
Dongdong Feng et al.
BLOOD (2018)
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero et al.
BLOOD (2018)
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Guillermo Montalban-Bravo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
M. G. Della Porta et al.
LEUKEMIA (2017)
Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CANCER (2017)
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
D. A. Sallman et al.
LEUKEMIA (2016)
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome
Moreno Festuccia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M. Zeidan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Koichi Takahashi et al.
ONCOTARGET (2016)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Wendy W. Pang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS
Aaron T. Gerds et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P. Chao et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
Mikkael A. Sekeres et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation
Sanjay Khandelwal et al.
TRANSFUSION (2007)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Role of CD47 as a marker of self on red blood cells
PA Oldenborg et al.
SCIENCE (2000)